Home Companies Catalysts Deep Dives
TAVNEOS avacopan APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaR&I
Launch2021-10-07
Peak Sales Est$800M
Formulations[{"id":"tavneos-oral","doses":"30mg capsule BID","route":"Oral","setting":"PATIENT_SELF","frequency"
Companies
AMGN (ORIGINATOR)100%
Mechanism: C5a receptor antagonist (oral)
Expert: Oral small molecule antagonist of complement C5a receptor (C5aR1). Inhibits C5a-mediated neutrophil activation and tissue damage in ANCA-associated vasculitis.
Everyday: Blocks the C5a receptor on immune cells, preventing the complement system from over-activating. The complement system normally fights infections, but in vasculitis it attacks your own blood vessels — this drug stops that friendly fire.
Targets: ["C5AR1"]
Revenue History
PeriodRevenue ($M)
2024$283M
2025$459M
Q4 2024$81M
Q4 2025$152M
Programs (1)
IndicationStageKey StudyRegional Status
ANCA vasculitisAPPROVEDADVOCATE[{"stage":"APPROVED","region":"US","approval_date":"2021-10-07"}]
Notes
RISK: FDA requested voluntary withdrawal Jan 2026 over ADVOCATE trial data integrity concerns. Amgen is contesting and will NOT withdraw. Binary outcome — either stays or gets pulled ($459M at risk). +62% YoY.
Data from Supabase · Updated 2026-03-24